Roca Therapeutics develops first-in-class small molecules targeting uveal melanoma and its associated neovascular complications, utilizing a platform focused on mechanisms of angiogenesis and chronic immunosuppressive inflammation. The company aims to provide effective treatment options for patients suffering from rare cancers and related ocular disorders, improving their quality of life and treatment outcomes.
Funding
Funding not disclosed
SSFounders
Product
Problem
Uveal melanoma, a rare cancer of the eye, lacks effective treatment options, and its neovascular complications, such as glaucoma and retinopathy following proton therapy, further impair vision and quality of life. Current therapies often fail to address the underlying mechanisms of angiogenesis and immunosuppressive inflammation that drive tumor growth and neovascularization.
Solution
Roca Therapeutics is developing first-in-class small molecule drugs that target the mechanisms of angiogenesis and chronic immunosuppressive inflammation associated with uveal melanoma and its neovascular complications. Their approach aims to provide a holistic treatment, addressing both the primary tumor and the secondary ocular disorders that arise from treatment. By targeting these key pathways, Roca Therapeutics seeks to offer more effective and targeted therapies for patients with uveal melanoma and related conditions.
Target Audience
The primary target audience includes patients suffering from uveal melanoma and its associated neovascular complications, as well as oncologists and ophthalmologists specializing in the treatment of these conditions.
Features
- Small molecule therapeutics targeting angiogenesis in uveal melanoma
- Compounds designed to modulate immunosuppressive inflammation within the tumor microenvironment
- Focus on neovascular complications, including glaucoma and retinopathy
- First-in-class molecules with patent protection
- Addressing both primary and metastatic forms of uveal melanoma